MedUni Vienna: Cardiovascular diseases: prognostic model from the 1990s still gives the best results
The so-called Framingham cardiovascular risk calculator was developed in 1991 on the basis of data gathered in the USA...
Das Computergraphik-Team der TU Wien simuliert Augenkrankheiten am Computer. Damit können gesunde Menschen besser...
Im Rahmen der Hauptversammlung der Österreichischen Forschungsgemeinschaft (ÖFG) ist Katharina Koch-Trappel am 25....
Twitter @lifesciencevieTweets @lifesciencevie
SY-Stem - a symposium focusing on the next generation of stem cell researchers – is an annual meeting, located in the...
Stay at the forefront of European biotech developments in an intimate setting unlike any other.
BIO-Europe Spring will be held in Vienna, Austria, in 2019 and is hosted by LISAvienna.
Political stability is a major factor when considering major investments in a country. Austria scores very highly in that regard, as it does in terms of infrastructure and standard of living. Without a doubt, however, one of the most important considerations for a research-driven company is research subsidies. This also played a decisive role in the decision to invest 700 million euros in the construction of our new biopharmaceutical production facility in Vienna. We are looking for highly qualified candidates to fill the 500 new positions, created for this project, and attach great importance for that reason to the training and qualifications of potential employees.
Philipp von Lattorff
Managing Director at Boehringer Ingelheim RCV GmbH & Co KG